A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).

The present disclosure provides methods of treating cancer by silencing tumor-innervating sensory neurons. The methods include treating cancer by genetic ablation of ion channels (e.g., TRPV1 or Na.sub.V1.8), local pharmacological silencing or blockade of neuropeptide release from tumor-innervating nociceptor (e.g., with QX-314 and BoNT/a), as well as the antagonism of the CGRP receptor RAMP1 (e.g., with BIBN 4096).

The present disclosure provides methods of treating cancer by silencing tumor-innervating sensory neurons. The methods include treating cancer by genetic ablation of ion channels (e.g., TRPV1 or Na.sub.V1.8), local pharmacological silencing or blockade of neuropeptide release from tumor-innervating nociceptor (e.g., with QX-314 and BoNT/a), as well as the antagonism of the CGRP receptor RAMP1 (e.g., with BIBN 4096).

Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents. The one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents may be delivered together with the direct factor Xa inhibitor and/or direct factor IIa inhibitor or separately from the direct factor Xa inhibitor and/or factor IIa inhibitor.

Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents. The one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents may be delivered together with the direct factor Xa inhibitor and/or direct factor IIa inhibitor or separately from the direct factor Xa inhibitor and/or factor IIa inhibitor.

A composition of isopropyl or ethyl alcohol, Cetylpyridinium Chloride and essential oils that enable the composition to have a prolonged antimicrobial effect by reducing the normal rate of alcohol dehydration, reducing toxicity and increasing duration of efficacy with proper application to oral cavity, oropharynx and directly pharyngeal tonsils.

A composition of isopropyl or ethyl alcohol, Cetylpyridinium Chloride and essential oils that enable the composition to have a prolonged antimicrobial effect by reducing the normal rate of alcohol dehydration, reducing toxicity and increasing duration of efficacy with proper application to oral cavity, oropharynx and directly pharyngeal tonsils.

A composition of isopropyl or ethyl alcohol, Cetylpyridinium Chloride and essential oils that enable the composition to have a prolonged antimicrobial effect by reducing the normal rate of alcohol dehydration, reducing toxicity and increasing duration of efficacy with proper application to oral cavity, oropharynx and directly pharyngeal tonsils.

The present invention relates to a composition and a method for use in diagnosing and treating bacterial infection. The composition comprises a novel compound with aggregation-induced emission characteristics adapted to target bacterial and biofilm with fluorescence. The compound is further adapted to generate reactive oxygen species for inhibiting and killing bacteria. The compound can be administered as a stand-alone anti-bacterial fluorescent modular probe or in combination with commercial drugs for enhanced therapeutic efficiencies with fewer side effects.

The present invention relates to a composition and a method for use in diagnosing and treating bacterial infection. The composition comprises a novel compound with aggregation-induced emission characteristics adapted to target bacterial and biofilm with fluorescence. The compound is further adapted to generate reactive oxygen species for inhibiting and killing bacteria. The compound can be administered as a stand-alone anti-bacterial fluorescent modular probe or in combination with commercial drugs for enhanced therapeutic efficiencies with fewer side effects.